View article

In their correspondence, V. Muthu and co-workers raise some issues related to our recent clinical trial “Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial” [1]. This provides a welcome opportunity to further explain the outcome of using a high dose of glucocorticoid for the treatment of patients with severe coronavirus disease 2019 (COVID-19).